Low-dose craniospinal radiation therapy for medulloblastoma

Area of Science:

• Pediatric Oncology
• Radiation Oncology
• Neuro-oncology

Background:

• Medulloblastoma treatment often involves craniospinal irradiation.
• Conventional doses may lead to significant long-term toxicity.
• Optimizing radiation doses while maintaining efficacy is crucial for pediatric patients.

Purpose of the Study:

• To evaluate the efficacy and toxicity of reduced-dose craniospinal irradiation combined with chemotherapy in children with medulloblastoma.
• To compare outcomes between low-dose and high-dose irradiation groups.

Main Methods:

• Retrospective analysis of 65 children with posterior fossa medulloblastoma treated postoperatively.
• Comparison of high-dose (54 Gy posterior fossa) versus low-dose (24-30 Gy whole brain/spine) craniospinal irradiation with chemotherapy.
• Stratification of patients into good-risk and poor-risk groups based on clinical and pathological factors.

Main Results:

• Overall 5-year survival was 73% and freedom from disease progression was 68%.
• Low-dose irradiation with chemotherapy showed comparable survival and local control to high-dose irradiation.
• Patients receiving lower doses demonstrated potentially better intellectual and social function with no increase in central nervous system recurrence.

Conclusions:

• Reduced-dose craniospinal irradiation combined with chemotherapy is a viable option for medulloblastoma treatment.
• This approach may decrease treatment-related toxicity without compromising oncologic outcomes.
• Further studies are needed to confirm benefits in specific risk groups and explore chemotherapy's role in good-risk patients.